Skip to main content

Advertisement

SpringerLink
Log in

β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the safety and efficacy of mirabegron for patients with overactive bladder (OAB) that is unresponsive to antimuscarinic agents or is related to benign prostatic hyperplasia (BPH).

Methods

Fifty-two newly diagnosed OAB patients (M group) and 45 patients with OAB that was unresponsive to antimuscarinics (S group) received mirabegron 50 mg once daily and were evaluated by OAB symptom score (OABSS), IPSS-QOL index, and IPSS at the time of baseline, 4 and 8 weeks. Newly diagnosed OAB patients treated with antimuscarinic agents were compared as controls.

Results

Mirabegron was effective for 85.2 % in M group. Significant improvements were seen in each domain of OABSS, and there was no significant difference with antimuscarinic therapy. Mirabegron was efficacious for 61.6 % of S group, and significant decreases of OABSS and IPSS-QOL index were observed. Significant improvements were also seen in voiding symptoms in men. Post-void residual urine volumes before and after treatment were 32.1 and 34.8 ml, and 26.2 and 31.3 ml in M and S group, respectively, and there was no significant difference. The incidence of adverse events was 8.4 %, although none were serious, and the patients recovered spontaneously after mirabegron was discontinued.

Conclusion

The present study suggests mirabegron is as effective as antimuscarinics for OAB. It improves OAB symptoms in patients with OAB for which antimuscarinic agents are insufficient. This study revealed that mirabegron improves not only OAB symptoms related to BPH, but also voiding symptoms in men. Low and mild incidences of side effects support the safe utility of mirabegron.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6:S580–S590

    PubMed  CAS  Google Scholar 

  2. D’Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R (2008) Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 14:291–301

    PubMed  Google Scholar 

  3. Benner JS, Nichol MB, Rovner ES et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276–1282

    Article  PubMed  Google Scholar 

  4. Wein AJ, Andersson KE (2007) Pharmacologic management of storage and emptying failure. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh Urology, 9th edn. Saunders Elsevier, Philadelphia, pp 2093–2094

    Google Scholar 

  5. Igawa Y, Yamazaki Y, Takeda H et al (1999) Functional and molecular biological evidence. Br J Pharmacol 126:819–825

    Article  PubMed  CAS  Google Scholar 

  6. Takeda M, Obara K (1999) Evidence for beta3-adrenoreceptor subtypes. J Pharmacol Exp Ther 288:1367–1373

    PubMed  CAS  Google Scholar 

  7. Yamaguchi O (2002) Beta3-adrenreceptor in human. Urology 59(5 Suppl 1):25–29

    Article  PubMed  Google Scholar 

  8. Fujimura T, Tamura K (1999) Expression and possible functional role of beta3- adrenoceptor in human and rat detrusor muscle. J Urol 161:680–685

    Article  PubMed  CAS  Google Scholar 

  9. Woods M, Carson N (2001) Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 166:1142–1147

    Article  PubMed  CAS  Google Scholar 

  10. Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647

    Article  PubMed  CAS  Google Scholar 

  11. Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C (2012) Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 110(2 Pt 2):E132–E142. doi:10.1111/j.1464-410X.2012.11240.x

    Article  PubMed  CAS  Google Scholar 

  12. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318–323

    Article  PubMed  Google Scholar 

  13. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817–820

    Article  PubMed  CAS  Google Scholar 

  14. Astellas, Betanis (mirabegron) package insert version 3, March 2012. PMDA. http://www.info.pmda.go.jp/downfiles/ph/PDF/80126_2590014F1021_1_02.pdf. Accessed 10 Aug 2012

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Nagakubo Hospital, 6907-1, Yaho, Kunitachi, Tokyo, 186-0011, Japan

    Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Yoshitaka Kuwahara & Takuji Tsukamoto

  2. Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Takeo Kosaka

  3. Mishima Hinyokika Clinic, 3-3-1, Shinmachi, Ome, Tokyo, 198-0024, Japan

    Junnji Mishima

Authors
  1. Hideo Otsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeo Kosaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenzo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junnji Mishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Kuwahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuji Tsukamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Otsuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Otsuki, H., Kosaka, T., Nakamura, K. et al. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol 45, 53–60 (2013). https://doi.org/10.1007/s11255-012-0343-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-012-0343-5

Keywords

Search

Navigation